Results of clinical tests performed in healthy controls and in patients with psoriasis (also divided in arthritic and not arthritic and in treated and not treated with biological drugs)
| Clinical tests | Controls (n=28) | Psoriasis (n=66) | Arthritis (n=26) | No arthritis (n=40) | Biological treatment (n=30) | No Biological treatment (n=36) |
| OSDI | 10.4±7.7 | 18.9±16.9* | 19.1±16.8* | 19.1±17* | 15.7±13.8* | 21.4±18* |
| Meibometry | 360.6±155.2 | 372.5±128.8 | 361.1±180.4 | 366.9±147.8 | 355.9±145.6 | 369.6±152.7 |
| Tearscope | 4.7±1.8 | 2.7±1.9* | 3±1.9* | 2.6±2* | 3.1±2.4* | 3.5±2.6* |
| TBUT | 6±1.6 | 3.2±1.6* | 3±1.6* | 3.6±1.9* | 3.3±1.6* | 3.2±1.6* |
| Conjunctiva | 1.4±1.3 | 2.3±1.9* | 1.9±2 | 2.1±1.9 | 2.4±1.9* | 2.3±2* |
| Cornea | 0.3±0.5 | 0.8±1.1* | 1±1.4*† | 0.4±0.9 | 0.5±0.9 | 1.1±1.5*‡ |
| Schirmer I | 24.2±10.1 | 17.5±11.9* | 16.5±10.8* | 17.3±13.4* | 19.9±12.6 | 16.6±13* |
| Aesthesiometry | 6±0.1 | 5.8±0.3* | 5.8±0.3* | 5.8±0.4* | 5.7±0.4* | 5.8±0.5* |
| MGD | 1.5±1.1 | 2.2±0.8* | 2.4±0.7* | 2.2±0.8* | 2.2±0.9* | 2.7±0.8*‡ |
↵*p< 0.05 versus controls; †p=0.03 versus no arthritis; ‡p<0.05 versus biological treatment.
MGD, meibomian gland dysfunction; OSDI, Ocular Surface Disease Index; TBUT, tear film breakup time.